Kantarjian et al53 assessed the efficacy and security of dasatinib, as when compared with imatinib, for the main-line cure of CML-CP. 5 hundred and nineteen clients with freshly diagnosed CML-CP were randomly assigned to receive dasatinib at a dose of 100 mg after day-to-day (259 clients) or imatinib in a https://gsk-lsd1-dihydrochloride99876.thechapblog.com/28294090/5-simple-techniques-for-iwr-1